Breaking News:

U.S. SEC Mandates Chinese IPO Hopefuls to Provide Additional Risk Disclosures

News

Takeda’s EXKIVITY Gets FDA Greenlight For Non-Small Cell Lung Cancer

Replicate Bioscience Liftoffs with $40 Million in Series A Funding to Develop srRNA Technology

Biotech Fraud Elizabeth Holmes Starts Trial for Theranos Scheme

Market

Pharma

FDA Greenlights Jazz Pharmaceutical's Xywav for Idiopathic Hypersomnia

FDA Greenlights First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes

FDA Questions Safety of Roxadustat Ahead of AdComm Review

Opinion

Is Elon Musk's startup Neuralink the Future of Tech in Healthcare?

Pfizer and Moderna Are One of the Most ❤️ Companies in the US

It took a Pandemic for Americans to look up to Big Pharma

Money

Replicate Bioscience Liftoffs with $40 Million in Series A Funding to Develop srRNA Technology

Renovorx Files Initial Public Offering

Adagio Therapeutics Announces Closing of Pricing of Initial Public Offering

Intelligence

U.S. SEC Mandates Chinese IPO Hopefuls to Provide Additional Risk Disclosures

ICER Rejects Aduhelm’s Benefits to Patients

Alzheimer’s Association Slams Biogen’s $56K Aduhelm List Price

Breaking News:

News

Takeda’s EXKIVITY Gets FDA Greenlight For Non-Small Cell Lung Cancer

Replicate Bioscience Liftoffs with $40 Million in Series A Funding to Develop srRNA Technology

Biotech Fraud Elizabeth Holmes Starts Trial for Theranos Scheme

Market

Pharma

FDA Greenlights Jazz Pharmaceutical's Xywav for Idiopathic Hypersomnia

FDA Greenlights First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes

FDA Questions Safety of Roxadustat Ahead of AdComm Review

Opinion

Is Elon Musk's startup Neuralink the Future of Tech in Healthcare?

Pfizer and Moderna Are One of the Most ❤️ Companies in the US

It took a Pandemic for Americans to look up to Big Pharma

Money

Replicate Bioscience Liftoffs with $40 Million in Series A Funding to Develop srRNA Technology

Renovorx Files Initial Public Offering

Adagio Therapeutics Announces Closing of Pricing of Initial Public Offering

Intelligence

U.S. SEC Mandates Chinese IPO Hopefuls to Provide Additional Risk Disclosures

ICER Rejects Aduhelm’s Benefits to Patients

Alzheimer’s Association Slams Biogen’s $56K Aduhelm List Price

Subscribe to Our Newsletter

Support Journalism